Cargando…
Eight tips for the implementation of the first licenced peanut allergy oral immunotherapy into clinical practice
BACKGROUND: Shared learnings from the early use of novel therapies can aid in their optimization. The recent introduction of peanut oral immunotherapy (peanut OIT; Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp]) for peanut allergy addresses a significant unmet need but also highlights th...
Autores principales: | Portnoy, Jay, Ciaccio, Christina E., Beausoleil, Janet, Du Toit, George, Fineman, Stanley, Tilles, Stephen A., Zhang, June, Lawrence, Claire, Yassine, Mohamed, Mustafa, S Shahzad |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9088027/ https://www.ncbi.nlm.nih.gov/pubmed/35534909 http://dx.doi.org/10.1186/s13223-022-00671-5 |
Ejemplares similares
-
Long-term safety and immunologic outcomes of daily oral immunotherapy for peanut allergy
por: Bird, J. Andrew, et al.
Publicado: (2023) -
Peanut Immunotherapy: Stepping Towards Desensitization for Peanut Allergy
por: Hsu, Joyce
Publicado: (2020) -
Adjuvanted Immunotherapy Approaches for Peanut Allergy
por: Johnson-Weaver, Brandi T., et al.
Publicado: (2018) -
The global burden of illness of peanut allergy: A comprehensive literature review
por: Lieberman, Jay A., et al.
Publicado: (2021) -
Oral immunotherapy for peanut allergy: The pro argument
por: Chinthrajah, R. Sharon, et al.
Publicado: (2020)